Bio: I don't know---CADX just did their first post approval dilution (not two and debt in the same time period like SOMX)and frankly that is maybe a better adding opportunity than SOMX? its a choice based on where each stands.
CADX have growing sales and hospital penetration into formularies and that for me might be a better bet as they have acheived what SOMX has in basically half the time and half the dilutions? They are doing better commerializing their drug, but of course investors are insensed over the dilution! They fail to see that dilution is necessary for all these bios with newly approved drugs as a fact of life. Especially without partnerships or with weak partnerships. You can never wait until you need the cash to get it---you weaken the company and the PPS long term---like SOMX!
They also fail to see what happens using SOMX as a template when ya do it piecemeal and don't solve the issues surrounding why ya need the money in the first place!
It is what it is!
I am just not very confident P+G will bite here. Not sure, but very NOT confident! I don't see the reason unless they really think over time they can get OTC for this kind of drug no matter the dose level that would be on the counter? Sure P+G is analyzing it--but to move on it? The delay signals they are looking at it, but to move??????
I'd do a trade from under 0.50, but I doubt it gets there immediately. Its maybe in their future, if they don't either increase sales or find support from another---P+G???? So far the last year has not shown a strong reason for P+G to do it, but we will see?